ArticleNanoscale advances2025
Cobalt-nickel metal-organic frameworks (CNMs) as drug delivery agents for triple-negative breast cancer.
Article in Nanoscale advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most prevalent cancers worldwide, with triple-negative breast cancer (TNBC) representing a particularly aggressive subtype, making it difficult to treat, and is associated with a poor prognosis. However, chemotherapy is associated with challenges such as drug resistance, off-target toxicity, and limited efficacy, highlighting the need for more effective therapies. Nanocarriers, including liposomes, micelles, and dendrimers, offer improved drug delivery efficacy and reduced toxicity but face challenges in terms of stability and scalability. Metal-organic frameworks (MOFs) have emerged as promising drug delivery systems, particularly for combination therapies to overcome resistance in TNBC. In this study, cobalt-nickel metal-organic frameworks (CNMs) were synthesized and loaded with a combination of cisplatin (Cis), doxorubicin (Dox), and 5-fluorouracil (5-Fu) (MD-CNM) to develop a novel multidrug delivery system. The MD-CNM exhibited high biocompatibility, an efficient drug loading capacity of 95.44 ± 4.05%, and sustained release over 96 h. Moreover, the MD-CNM demonstrated potent cytotoxicity against MDA-MB-231 breast cancer cells, with an IC
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.